6472431

3 known cases. View patent page →

Cases
3
Active
0
3 closed
Filed
2014
Top venue
D. New Jersey
2 cases

Untitled case

terminated by settlement
Docket:
IPR2016-00370
Patents:6472431
Δ Jazz Pharmaceuticals, Inc.

Inter partes review involving the '431 patent. The petitioner was listed only as 'Unified Patents PTAB Data'; respondent/patent owner Jazz Pharmaceuticals. The proceeding terminated by settlement.

Jazz Pharmaceuticals, Inc. et al. v. Roxane Laboratories, Inc. et al.

settled
Docket:
2:10-cv-06108
Patents:785150664724317895059
π Jazz Pharmaceuticals, Inc.π Jazz Pharmaceuticals Ireland LimitedΔ Roxane Laboratories, Inc.Δ Hikma Pharmaceuticals USA, Inc.Δ West-Ward

Lead consolidated Hatch-Waxman action over Xyrem sodium oxybate. The ’506 patent was among the original patents-in-suit, along with the ’431, ’889, ’219, ’059, and the ’730 family. Resolved by settlement with no final judgment on the ’506 patent.

Jazz Pharmaceuticals, Inc. v. Ranbaxy Laboratories Limited et al.

consolidated/terminated
Docket:
2:14-cv-04467-ES-JAD
Filed:
2014-07-15
Terminated:
2015-04-22
Patents:84612036472431678088972622197851506826365083242757668730776510677651077895059845798885891828731963
π Jazz Pharmaceuticals, Inc.Δ Ranbaxy Laboratories LimitedΔ Ranbaxy Inc.

Jazz Pharmaceuticals sued Ranbaxy Laboratories and Ranbaxy Inc. in a Hatch-Waxman ANDA patent infringement action over generic sodium oxybate referencing Xyrem. The complaint asserted multiple patents including U.S. Patent No. 8,461,203. The case was consolidated for all purposes into Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, No. 13-391-ES-JAD, and administratively terminated.